Program
donidalorsen
Its studies are mostly in Angioedemas, Hereditary, led by Ionis Pharmaceuticals.
Furthest: phase 3, since Nov 18, 20216 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ionis Pharmaceuticals | 62 open or running | phase 3since Nov 18, 2021 | Aug 17, 2017 | Dec 2026phase 3 · NCT05392114 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2017First study: phase 1 study in Healthy VolunteersFirst studyNCT03263507 · 32 enrolled · Canada
- Jul 22, 2019Phase 2 study in Angioedemas, HereditaryNCT04030598 · 23 enrolled · United States, Netherlands
- Mar 11, 2020Phase 2 study in Angioedemas, HereditaryNCT04307381 · 20 enrolled · United States, Netherlands
- Nov 18, 2021Phase 3 study in Angioedemas, HereditaryNCT05139810 · 91 enrolled · United States, Belgium, Bulgaria and more
- May 23, 2022Phase 3 study in Angioedemas, HereditaryNCT05392114 · 154 enrolled · United States, Belgium, Bulgaria and more
- Dec 19, 2025Phase 3 study in Angioedemas, HereditaryNCT07298447 · 20 planned · United States, Australia, Italy and more
Ahead
- Dec 2026Primary completion: phase 3 study in Angioedemas, HereditaryNCT05392114
- Jun 2029Primary completion: phase 3 study in Angioedemas, HereditaryNCT07298447
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07298447Angioedemas, Hereditary · United States, Australia, Italy and more | 3 | Recruiting | Jun 2029 | 20 |
| NCT05392114Angioedemas, Hereditary · United States, Belgium, Bulgaria and more | 3 | Active, not recruiting | Dec 2026 | 154 |
| NCT05139810Angioedemas, Hereditary · United States, Belgium, Bulgaria and more | 3 | Completed | Nov 9, 2023 | 91 |
| NCT04307381Angioedemas, Hereditary · United States, Netherlands | 2 | Completed | Jan 24, 2025 | 20 |
| NCT04030598Angioedemas, Hereditary · United States, Netherlands | 2 | Completed | Jan 4, 2021 | 23 |
| NCT03263507Healthy Volunteers · Canada | 1 | Completed | Oct 9, 2018 | 32 |
How it is read
Names in the registry
- “Donidalorsen”, 6 entries
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.